Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02620605

The Influence of Timing of Cabergoline Initiation on Prevention of OHSS — OHSS  

Ovarian Hyperstimulation Syndrome Clinical Trial

Official title:
The Influence of Timing of Cabergoline Initiation on Prevention of Ovarian Hyper Stimulation Syndrome in Patients Undergoing Intra Cytoplasmic Sperm Injection .

Clinical Trial Summary

Study the effect of early cabergoline administration in prevention of occurrence or decreasing the severity of OHSS in patients undergoing intra cytoplasmic sperm injection.And its effect on oocyte maturation,fertilization and pregnancy rate..

Clinical Trial Description

Patients less than 35years undergoing Intra Cytoplasmic Sperm Injection for infertility scheduled for gonadotropin releasing hormone agonist long protocol of ovarian stimulation.

All patient will receive combined oral contraceptive pills (Gynera, Schering-plow: plough) starting from day 5 of cycle that precedes the stimulated cycle .On day 21 of that cycle all patients will start to receive Gonadotrophin releasing hormone agonist in the form of (decapeptyl 0.1 sc daily and continued till the day of HCG administration).

To ensure that all patients are completely down regulated and desensitized ,trans-vaginal ultrasound will be performed at day 2-3 of menses of stimulated cycle to ensure endometrial thickness less than 5 mm and no ovarian cysts.Also serum E2 level is less than 50 pg/ml.

Then all patients will start to receive Gonadotrophin ( HMG) (Menogon, ferring pharmaceuticals, Germany) 225 IU (international unit) Intramuscular Injection daily,with continuous scheduled follow up of ovarian response by serial trans -vaginal US to assess follicular growth together will serial serum E2 starting from day 6 of cycle and onwards.With adjustments of gonadotropin dose and monitoring frequency based on patient response.

During follow up once the recruited patients fulfilling the inclusion criteria (serum E2 equal or more than 4000 pg/ml and /or 18 or more follicles of 11 mm diameter or more at any day of stimulation),they will be allocated randomly by computer generated cards and assigned by sealed envelopes by the treating doctor at the outpatient clinic.

Group A : will receive cabergoline 0.5 mg/day for 8 days, starting in the day of HCG (human chorionic gonadotropin ) injection.

Group B: will receive cabergoline 0.5 mg/day once the criteria of inclusion criteria is fulfilled and continued till the day of human chorionic gonadotropin (HCG ) trigger and continued 8 days more from day of trigger . ;

Study Design

Related Conditions & MeSH terms

  • Ovarian Hyperstimulation Syndrome
  • Syndrome
Clinical Trial Details
NCT number NCT02620605
Study type Interventional
Source Cairo University
Contact Sherine H Gad Allah, MD
Phone 01097665573
Email sherinehosny@gmail.com
Status Recruiting
Phase Phase 3
Start date December 20, 2017
Completion date April 2019
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT00617864 - The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome N/A
Withdrawn NCT01979341 - The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes N/A
Completed NCT01427335 - Calcium for Prevention of Ovarian Hyperstimulation Syndrome Phase 3
Completed NCT01014104 - Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome Phase 1/Phase 2
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Completed NCT06333691 - Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin N/A
Terminated NCT01714648 - Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome? Phase 4
Completed NCT01500863 - Endometrial Receptivity After GnRH Agonist Triggering Phase 4
Recruiting NCT00417144 - Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Phase 4
Completed NCT03876145 - The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome N/A
Completed NCT05588635 - Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
Not yet recruiting NCT02392520 - Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) N/A
Completed NCT00835523 - Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist N/A
Completed NCT00665041 - Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome Phase 2
Active, not recruiting NCT05638529 - Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome Phase 4
Not yet recruiting NCT03071172 - Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET Phase 3
Recruiting NCT02084940 - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF N/A
Completed NCT01815138 - Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Phase 4
Completed NCT00867659 - The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors N/A
Completed NCT01569256 - Ovarian Hyperstimulation Syndrome and Cabergoline N/A